Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7348888 | 0.85 | ARG1 (0.31) | ARG1ARG2 | |
| SCHEMBL7298166 | 0.79 | — | — | |
| SCHEMBL7338385 | 0.78 | ARG1 (0.35) | ARG1ARG2 | |
| SCHEMBL7338721 | 0.78 | ARG1 (0.35) | ARG1ARG2 | |
| SCHEMBL10584390 | 0.75 | — | — | |
| SCHEMBL7340984 | 0.73 | ARG1 (0.36) | ARG1ARG2 | |
| SCHEMBL6975551 | 0.73 | ARG1 (0.33) | ARG1ARG2 | |
| SCHEMBL27609068 | 0.72 | NPSR1 (0.32) | ARG1ARG2 | |
| SCHEMBL11386528 | 0.71 | ARG1 (0.33) | ARG1ARG2 | |
| SCHEMBL11386115 | 0.70 | ARG1 (0.31) | ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108084113-B | Preparation method of pramipexole impurity | 江苏恒瑞医药股份有限公司 | 2021-05-14 | — | — | CN | claimed |
| CN-108084113-B | Preparation method of pramipexole impurity | 江苏恒瑞医药股份有限公司 | 2021-05-14 | — | — | CN | disclosed |
| US-10633630-B2 | Acceleration of Mycobacterium growth | ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) | 2020-04-28 | — | — | US | disclosed |
| EP-3158053-B1 | ACCELERATION OF MYCOBACTERIUM GROWTH | ST GEORGES HOSPITAL MEDICAL SCHOOL (GB) | 2019-03-13 | — | — | EP | disclosed |
| US-9969770-B2 | Proline compounds as Granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2018-05-15 | — | — | US | disclosed |
| US-9707282-B2 | Small cationic antimicrobial peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-07-18 | — | — | US | disclosed |
| US-20170121672-A1 | ACCELERATION OF MYCOBACTERIUM GROWTH | ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) | 2017-05-04 | — | — | US | disclosed |
| US-20170015706-A1 | PROLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2017-01-19 | — | — | US | disclosed |
| US-9458193-B1 | Proline compounds as Granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2016-10-04 | — | — | US | disclosed |
| US-20150315240-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-11-05 | — | — | US | disclosed |
| US-9017656-B2 | Small cationic antimicrobial peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-04-28 | — | — | US | disclosed |
| EP-2061886-B1 | Small cationic immunomodulatory peptides | UNIV BRITISH COLUMBIA (CA) | 2014-05-07 | — | — | EP | disclosed |
| US-20130266597-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-10-10 | — | — | US | disclosed |
| US-8343475-B2 | Small cationic antimicrobial peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-01-01 | — | — | US | disclosed |
| EP-2061886-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | The University of British Columbia (CA) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008022444-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-02-28 | — | — | WO | disclosed |
| US-5629406-A | AMINO ACID DERIVATIVES | SANKYO COMPANY, LIMITED (JP) | 1997-05-13 | — | — | US | disclosed |
| US-4316906-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015706-A1 | PROLINE COMPOUNDS AS GRANZYME B INHIBITORS | GZMB, CTSB, RNPEP | ARG1 212/4885ARG2 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.